Cyclic hydroxamic acids as chemosensibilizators of cytostatic therapy
Vol. 70 No. 3 (2024), Articles
Vol. 70 No. 3 (2024)

Cyclic hydroxamic acids as chemosensibilizators of cytostatic therapy

Articles
https://doi.org/10.37469/0507-3758-2013-59-5-620-622
Published 15.12.2013
Institute of Problems of Chemical Physics of the Russian Academy of Sciences
Institute of Problems of Chemical Physics of the Russian Academy of Sciences
Institute of Problems of Chemical Physics of the Russian Academy of Sciences
Institute of Problems of Chemical Physics of the Russian Academy of Sciences
Institute of Problems of Chemical Physics of the Russian Academy of Sciences
Institute of Problems of Chemical Physics of the Russian Academy of Sciences
Institute of Problems of Chemical Physics of the Russian Academy of Sciences
Institute of Problems of Chemical Physics of the Russian Academy of Sciences
Institute of Problems of Chemical Physics of the Russian Academy of Sciences
Institute of Problems of Chemical Physics of the Russian Academy of Sciences

Abstract

In experimental animals with tumors it was studied antitumor activity of spirocyclic hydroxamic acids which could be classified as targeted agents as their target was enzyme histonedeacetylase, which was involved in the neoplastic process. The results showed that the hydroxamic acids were chemosensibilizators of anticancer agents increasing their efficacy and enabling significantly reduce the therapeutic dose. Also it was showed that hydroxamic acid, containing nitrogen mustard, was effective in the action on tumors with phenotype and genotype of multidrug resistance.
https://doi.org/10.37469/0507-3758-2013-59-5-620-622
PDF (Русский)

References

Гончарова С.А., Демидова Н.С., Ширяева О.А. и др. Характеристика антрациклинустойчивых штаммов лейкоза Р388 // Экспер. онкол. 1987. - Т. 9. - № 4. - С. 42 - 47.

Демидова Н.С., Гончарова С.А., Чернова О.Б. и др. Амплификация генов в лейкозных клетках мыши с приобретенной in vivo множественной лекарственной устойчивостью // Генетика, 1987. - Т. 23. - № 10. - С. 1797 - 1806.

Имянитов Е.Н. Общие представления о таргетной терапии // Практ. онкол. 2010. - Т. 11. - № 3. - С. 123 - 130.

Переводчикова Н.И., Феденко А.А. Особенности методики клинических испытаний таргетных препаратов // Росс. биотерапевт. Журн. — 2009. - Т. 8. - № 2. - С. 77 - 78.

Трещалина Е.М., Жукова О.С., Герасимова Г.К. и др. Методические указания по изучению противоопухолевой активности фармакологических веществ //

http://www.oncology.ru/specialist/treatment/preclinical/precl/metod.pdf.

Luong Q. T., ’Kelly J. O., Braunstein G. D. et al. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo // Clin Cancer Res. -2006. - Vol. 12. - P. 5570 - 5577.

E. Pontiki, D. Hadjipavlou-Litina, Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSAR perspectives // Med. Res. Rev., 2012. - Vol. 32. - P. 1-165.

Roberts H. L. Antitumor effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in combination with the microtubule-stabilizing agent paclitaxel on breast cancer cells // MURJ. — 2006. - Vol. 13. - P. 37 - 43.

Steele N. L., Plumb J. A., Vidal L. et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101) // Cancer Chemother Pharmacol. — 2011. - Vol. 67. - P. 1273 - 1279.

Ververis K., Hiong A., Karagiannis T.C., Licciardi P.V. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents // Biologics: Targets and Terapy, 2013. - Vol. 7. - P. 47 - 60.

Vystorop I. V., Konovalova N. P., Sashenkova T. E. et al. 1-Hydroxy-8-methyl-1,4,8-triazaspiro[4.5]decan-2-one and its (±)-3-methyl homologue: regioselective synthesis and in vivo evaluation as adjuvants in leukemia chemotherapy // Mendeleev Commun., 2011. - Vol. 21. - P. 239 - 241.

Zhang Y., Feng J., Jia Y. et al., Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities // J Med. Chem. 2011. - Vol. 5 4. - P. 2823 - 2838.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...